Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03278704
Other study ID # RG_16-218
Secondary ID ERN_16-1612RRK60
Status Terminated
Phase N/A
First received
Last updated
Start date December 6, 2017
Est. completion date July 12, 2018

Study information

Verified date July 2018
Source University of Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is recommended that individuals perform a combination of resistance exercise (RE) and endurance exercise. Lack of time is often cited as a reason for being unable to meet current exercise guidelines. Therefore, combining both forms in one session may be beneficial. However, research continues to elucidate whether interference of adaptive outcomes occurs when RE and endurance exercise are performed concurrently. A proposed interference effect suggests that concurrent training may dampen RE-induced adaptations (e.g., muscle strength and growth) compared to RE only.

The propose of this investigation is to determine the effects of concurrent RE and high-intensity interval training (HIIT), compared to RE only, on muscle health and cardiovascular risk in sedentary, middle-aged (40-65 years) who are overweight/obese with type 2 diabetes mellitus (T2DM). The investigators will measure the effects on muscle strength, muscle growth, cardiovascular fitness, glycaemic control and markers of cardiovascular risk before and after an 8-week training program. Data will be obtained through the analysis of skeletal muscle samples, blood samples, magnetic resonance imaging, questionnaires and exercise performance tests.It is hypothesized that concurrent RE + HIIT will amplify the exercise-induced muscle growth response, which will result in greater satellite cell content, compared to RE alone. As a result, this will lead to greater skeletal muscle mass and strength after RE + HIIT compared to RE in isolation.

A finding that concurrent resistance training and HIIT does not impede muscle adaptations could offer future strategies to minimize exercise time commitment whilst still maximizing the physiological benefits of both resistance and endurance exercise through a single training session. This may therefore provide an effective exercise strategy in the prevention and/or treatment of T2DM.


Description:

Data analysis will be performed using IBM SPSS statistical software (IBM Corp., Armonk, New York, USA). All data will be checked for normality and appropriate log transformations applied prior to analysis of variance (ANOVA) for primary and secondary outcomes. Satellite cell content will be compared using a two-way, mixed-model ANOVA with one within (2 levels; pre- and post-training) and one between factor (2 level; exercise group) with significance set at P < 0.05.

Based on a mixed ANOVA with between- and within-participant factors, and previously published data (Babcock et al. 2012), a sample size of 24 participants (12 per group) will provide a power of 84%. This sample size will allow detection of a mean change in satellite cell content of 2.35, assuming standard deviations of the change from pre- to post-training as 2.266 and 1.331 in the two exercise groups. Sample size calculation was performed with an alpha error of 0.05. SamplePower 2.0 (SPSS Inc., Chicago, Illinois, USA) software was used to determine sample size.

This study will combine data collected at the University of Birmingham with previously collected data from an identical study design performed by a co-investigator (Dr Pugh) in Rome, Italy. The previous study has collected data from 10 participants across both exercise groups (RE, N = 7; RE + HIIT, N = 3). Therefore, it is necessary for the present study to recruit a further 14 participants (RE, N = 5, RE + HIIT, N = 9) in order to achieve a sample size of 24 participants (12 per group). However, based on an assumption of a 25% drop-out rate, the total minimal sample necessary will be 19 participants (RE, N = 7; RE + HIIT, N = 12).


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date July 12, 2018
Est. primary completion date July 12, 2018
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria:

- Male sex

- White British/European

- Aged between 40 and 65 years at the time of screening

- Have a body mass index (BMI; body weight/height in m2) between 27 and 40 kg/m2

- Sedentary/untrained for at least 1 year (based on physical activity self-reports of fewer than two sessions of structured exercise per week last <30 min)

- T2DM (American Diabetes Association 2014) for more than 1 year

- Central obesity (defined as waist circumference =94 cm for males)

Exclusion Criteria:

- Currently involved in research or have recently (<6 months) been involved in any research prior to recruitment

- Any condition limiting or contraindicating physical activity; including diabetic peripheral neuropathy, and coronary or peripheral artery disease

- Previous myocardial infarction, previous or current angina, shortness of breath, or other symptoms suggestive of heart failure

- Insulin medication

- HbA1c more than 75 mmol/mol (9%)

- Uncontrollable hypertension: systolic blood pressure =160 mmHg and diastolic blood pressure =100 mmHg

- Not weight stable for the last three months

- Smokers (within the last 12 months)

- Anticoagulant medication, such as warfarin or newer anticoagulant drugs. If participants are on aspirin medication, this would need to be stopped for 3 days prior to and during the day of any biopsy visit unless contraindicated (in which case participants would be excluded).

Study Design


Intervention

Other:
RE only
8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
RE + HIIT
8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.

Locations

Country Name City State
United Kingdom School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham Birmingham

Sponsors (4)

Lead Sponsor Collaborator
University of Birmingham Loughborough University, Metabolic Fitness Association, Italy, Università degli studi di Roma Foro Italico

Country where clinical trial is conducted

United Kingdom, 

References & Publications (2)

American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014. — View Citation

Babcock L, Escano M, D'Lugos A, Todd K, Murach K, Luden N. Concurrent aerobic exercise interferes with the satellite cell response to acute resistance exercise. Am J Physiol Regul Integr Comp Physiol. 2012 Jun 15;302(12):R1458-65. doi: 10.1152/ajpregu.00035.2012. Epub 2012 Apr 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in fibre-type specific satellite cell content Assessed using immunofluorescence microscopy (Pax7-positive cells) Prior to the 8-week training intervention and 72 hours after the last training session
Secondary Change in muscle-specific gene expression related to growth adaptations Assessed using reverse-transcription polymerase chain reactions Prior to the 8-week training intervention and 72 hours after the last training session
Secondary Change in muscle fibre size Assessed using immunofluorescence microscopy techniques to determine muscle fibre type-specific cross-sectional area Prior to the 8-week training intervention and 72 hours after the last training session
Secondary Change in muscle size Assessed using MRI to determine whole and individual muscle group cross-section area and total muscle volume Prior to the 8-week training intervention and 48 hours after the last training session
Secondary Change in isometric muscle strength Assessed using a dynamometer Prior to the 8-week training intervention and 6 days after the last training session
Secondary Change in isokinetic muscle strength Assessed using a dynamometer Prior to the 8-week training intervention and 6 days after the last training session
Secondary Change in cardiorespiratory fitness Assessed using a V?O2 peak test on a cycle ergometer Prior to the 8-week training intervention and 6 days after the last training session
Secondary Change in habitual physical activity levels Assessed using 7-day continuous accelerometry data Prior to the 8-week training intervention and 1 week after the last training session
Secondary Change in exercise enjoyment Assessed using validated questionnaires (PACES) After the first and last training session
Secondary Change in glycaemic control Assessed using blood analysis Prior to the 8-week training intervention and 72 hours after the last training session
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02226003 - Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) Phase 3